We've built the world's largest library of clinical and molecular data in oncology. Genomic sequencing, pathology, imaging, clinical records — all connected. That data set doesn't exist anywhere else.
My wife was diagnosed with breast cancer. The oncologist had almost no data to personalize her treatment. In 2015. I thought: this is insane. We have more data on what movies people watch than on how to treat their cancer.
I co-founded Groupon. Built it to a $30 billion IPO. It was the fastest-growing company in history at the time. Tempus is harder. But it matters more. Coupons versus cancer. Easy choice.
We went public in 2024 at a $6 billion valuation. For a precision medicine company. Not a drug company — a data company that helps doctors choose the right drug. That's a new category.
Doctors are making life-and-death decisions with incomplete data every single day. Tempus gives them the full picture — genomics, imaging, clinical history — so the decision is informed, not intuitive.
We partner with every major cancer center in the US. Over 50% of oncologists in America use Tempus. When you have that kind of adoption, the data flywheel becomes unstoppable — more data, better insights, more adoption.